Product
Recombinant influenza vaccine (RIV4)
1 clinical trial
1 indication
Indication
Influenza ImmunizationClinical trial
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.Status: Terminated, Estimated PCD: 2023-10-03